OnKure Therapeutics (OKUR) AI Stock Analysis

• Market Cap: $41.94M
• Dividend Yield: N/A
• Average Volume (3M): 86.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: N/A
• EPS Growth: 46.20%
• Country: US
• Employees: 46
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.09
• Shares Outstanding: 12,843,434
• 10 Day Avg. Volume: 131,167
• 30 Day Avg. Volume: 86,556
• PEG Ratio: -0.04
• Price to Book (P/B): 1.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.24
• Enterprise Value/Market Cap: -1.20
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 119.96
• Enterprise Value/Ebitda: 0.65
• 1Y Price Target: $25.50
• Price Target Upside: 791.61% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: ―

OnKure Therapeutics is experiencing significant financial challenges with no revenue and persistent losses, impacting its financial performance score. The technical analysis indicates a bearish trend, compounded by a negative MACD and oversold RSI and Stochastic levels, suggesting caution. Valuation is weak due to a negative P/E ratio, highlighting the need for substantial operational improvements. Overall, the company's stock presents high risk, requiring strategic shifts to enhance financial health and investor appeal.

Positive Factors

Partnership Revenue Model

OnKure's revenue model, based on strategic partnerships and licensing, provides a scalable path to revenue growth, leveraging larger firms' resources.

Equity Position Improvement

Improved equity position enhances financial stability and investor confidence, providing a stronger foundation for future growth initiatives.

Cash Flow Management

Effective cash flow management and capital sourcing bolster liquidity, enabling continued investment in R&D and operational activities.

Negative Factors

Lack of Revenue

The absence of revenue highlights operational challenges and underscores the need for successful commercialization to achieve profitability.

Persistent Losses

Ongoing losses without revenue generation strain financial resources, necessitating strategic shifts to improve operational efficiency and growth.

High Operational Costs

High operational costs without offsetting revenue increase financial risk, requiring cost management and efficiency improvements for sustainability.

OnKure Therapeutics Business Overview & Revenue Model

Company Description

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

How the Company Makes Money

OnKure Therapeutics generates revenue primarily through partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These agreements often include upfront payments, milestone payments based on the achievement of specific development or regulatory objectives, and royalties on future sales of successfully commercialized drugs. Additionally, OnKure may receive funding from government grants or research institutions to support its R&D activities. The company's revenue model is highly dependent on the progress and success of its clinical trials and the ability to secure strategic partnerships.

OnKure Therapeutics Financial Statement Overview

Summary

OnKure Therapeutics faces considerable financial management challenges, with persistent losses and no revenue. While recent improvements in equity and financing activity are positive signals, the company needs to focus on revenue generation and operational efficiency to achieve sustainable growth.

Income Statement

OnKure Therapeutics has not generated any revenue over the past three years, resulting in negative EBIT and net income figures. The lack of revenue and high operational losses indicate significant financial challenges and a need for strategic shifts to achieve profitability.

Balance Sheet

The company shows improvement in its equity position with positive stockholders' equity in the latest year, reversing the negative equity from previous years. However, the low debt levels relative to equity indicate limited leverage risk, albeit with significant liabilities. The equity ratio shows a strong position in total assets.

Cash Flow

The company exhibits strong cash flow management, with significant financing inflows enhancing cash reserves. Despite negative operating cash flow, the increase in cash and equivalents signals effective capital sourcing. However, substantial free cash outflows continue to reflect operational challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-419.00K	0.00	0.00	0.00	-50.00K	-37.00K
EBITDA	-77.62M	-51.71M	-34.75M	-29.38M	-39.72M	-19.43M
Net Income	-81.21M	-52.67M	-35.31M	-29.51M	-39.77M	-19.46M
Balance Sheet
Total Assets	72.83M	114.91M	35.73M	16.00M	154.02M	55.22M
Cash, Cash Equivalents and Short-Term Investments	70.33M	110.76M	29.88M	11.54M	147.67M	53.61M
Total Debt	687.00K	1.08M	674.00K	637.00K	0.00	92.72M
Total Liabilities	6.41M	11.08M	137.58M	70.42M	6.81M	97.34M
Stockholders Equity	66.43M	103.83M	-101.84M	-54.42M	147.21M	-42.12M
Cash Flow
Free Cash Flow	-61.42M	-51.17M	-34.79M	-28.09M	-38.18M	-18.56M
Operating Cash Flow	-61.33M	-51.12M	-34.55M	-26.95M	-37.98M	-18.54M
Investing Cash Flow	-45.41M	15.87M	-246.00K	-1.13M	-23.38M	7.38M
Financing Cash Flow	114.14M	116.13M	53.13M	26.46M	132.41M	47.27M

OnKure Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OKUR, the sentiment is Positive. The current price of 2.86 is below the 20-day moving average (MA) of 3.00, below the 50-day MA of 2.94, and below the 200-day MA of 3.04, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 52.05 is Neutral, neither overbought nor oversold. The STOCH value of 51.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OKUR.

OnKure Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OKUR	42 Neutral	$41.94M	-0.58	-115.64%	―	―	46.20%
ELUT	42 Neutral	$39.00M	-0.87	―	―	-14.92%	72.81%
IGC	41 Neutral	$35.78M	-4.85	-83.34%	―	-6.51%	58.31%
SONN	40 Underperform	$22.65M	-0.39	―	―	1689.52%	66.05%
RANI	32 Underperform	$196.86M	―	―	―	―	25.08%

OnKure Therapeutics Corporate Events

OnKure Therapeutics Advances Cancer Drug Trials

OnKure Therapeutics has released promising early data from its PIKture-01 trial, showcasing the safety and efficacy of OKI-219, a selective PI3KαH1047R inhibitor, in treating various cancers. The drug demonstrated excellent tolerability and robust anti-tumor activity, with plans to advance its combination trials with fulvestrant. Investors can expect further insights and combination data by late 2025, positioning OnKure as a potential leader in precision oncology therapies.